title: [Transfusion of platelet concentrates].
abstract: Although a number of research have been realized in the aim of decreasing the use of platelet concentrates, these blood products remain absolutely necessary for patients with therapeutic aplasia and for some surgical patients. After the description of the main rules of platelet transfusion procedures, we will discuss some controversial issues: threshold value for platelet transfusion, platelet doses, place of curative and prophylactic strategies, refractoriness to platelet transfusion, HLA alloimmunization. Then we will focus our review on the future alternatives for platelet transfusion.
authors.affiliation: Unité de Médecine Transfusionnelle et d'Hémovigilance, Hôpital Henri-Mondor, Créteil.
authors.forename: C
authors.initials: C
authors.lastname: Rieux
authors.forename: K
authors.initials: K
authors.lastname: Lee
authors.forename: A
authors.initials: A
authors.lastname: Lavaud
authors.forename: P
authors.initials: P
authors.lastname: Bierling
mesh_terms: D001782:Blood Donors; D001792:Blood Platelets / Q000276:immunology; D016207:Cytokines / Q000276:immunology / Q000627:therapeutic use; D005260:Female; D006680:HLA Antigens / Q000276:immunology; D006470:Hemorrhage / Q000628:therapy; D006650:Histocompatibility Testing; D006801:Humans; D007518:Isoantibodies / Q000276:immunology; D008297:Male; D008954:Models, Biological; D017713:Platelet Transfusion / Q000009:adverse effects / Q000592:standards; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013156:Splenectomy; D013921:Thrombocytopenia / Q000209:etiology / Q000628:therapy
chemical_list: D016207:Cytokines; D006680:HLA Antigens; D007518:Isoantibodies